Results 231 to 240 of about 174,174 (316)
Models of Propositional Calculi in Recursive Arithmetic.
R. L. Goodstein
openalex +2 more sources
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana+8 more
wiley +1 more source
BMWP: the first Bengali math word problems dataset for operation prediction and solving. [PDF]
Mondal S+4 more
europepmc +1 more source
Abstract Berzosertib is a small‐molecule ataxia telangiectasia and Rad3‐related protein inhibitor. To assess the clearance mechanism(s) of berzosertib, a Phase 1, 2‐period, open‐label study was conducted in adults with advanced solid tumors who were treated with a single intravenous dose of 210 mg/m2 berzosertib containing approximately 3 µCi of [14C ...
Jayaprakasam Bolleddula+12 more
wiley +1 more source
Camlipixant in Refractory Chronic Cough: A Phase 2a, Randomized Controlled Trial (RELIEF). [PDF]
Smith JA+13 more
europepmc +1 more source
Abstract A modified controlled‐release sodium valproate formulation (VAL001, test) was compared with an approved enteric‐coated tablet formulation (Absenor, reference). Pharmacokinetics and safety/tolerability were evaluated in healthy subjects to bridge with positive efficacy results from an early‐phase patient trial of valproate in combination with ...
Nikhil Ahuja+8 more
wiley +1 more source
Approaches for Reducing Expert Burden in Bayesian Network Parameterization. [PDF]
Blomaard BPM, Nane GF, Hanea AM.
europepmc +1 more source
Abstract A pediatric‐friendly powder for oral suspension (PfOS) of tovorafenib, a type II RAF inhibitor, was developed for patients with difficulty swallowing tablets. This open‐label, randomized, phase 1 study (QSC205140) evaluated the taste/palatability of PfOS formulations (n = 12), the relative bioavailability of the PfOS versus tablet formulation,
Yang Zhang+6 more
wiley +1 more source
A Technology-Driven Assistive Learning Tool and Framework for Personalized Dyscalculia Interventions. [PDF]
Jadhav D+3 more
europepmc +1 more source